Table 1. Summary of comparative studies meeting inclusion criteria for analysis.

Study	Country	Study period	Paints (n)	Stone size (mm)	Stone location	Additional medications	I/C # (mg/day)	F (weeks)	Study quality*
Pedro[15]	USA	2008	34 35	3.96 3.67	LU	NR	Alfuzosin 10 mg Control	4	5
Cha[12]	Korean	2012	36 30 34	5.81 5.73 5.59	LU	Trospium chloride (50 mg, tablet) every 8 hours	Alfuzosin 10 mg Tamsulosin 0.4mg Control	4	5
Ibrahim[11]	Iraq	2013	40 40 32	5.94 5.58 5.65	UU LU	Diclofenac potassium orally 50 mg and/or diclofenac sodium as an intramuscular injection of 75 mg on demand	Alfuzosin 10 mg Tamsulosin 0.4 mg Control	4	4
Gurbuz[16]	Turkey	2011	34 33	6.83 7.13	LU	Drink at least 3 L of fluids daily; Diclofenac injection (75 mg) intramuscularly on demand for pain relief	Alfuzosin 10 mg Control	2	4
Chau[18]	China	2011	33 34	6.7 6.9	UU LU	Dologesic (paracetamol+dextropropoxyphene) 4 tablets daily on a demand basis for 2 weeks	Alfuzosin10 mg Control	6	3
Agrawal[13]	India	2008	34 34 34	6.70 6.17 6.35	LU	Drink at least 3 L of fluids daily; Diclofenac injection (75 mg) intramuscularly on demand for pain relief	Alfuzosin10 mg Tamsulosin 0.4 mg Control	4	5
Ahmed[14]	KSA	2010	30 30 28	5.47 4.97 5.39	LU	Diclofenac sodium (50 mg, tablet) every 12 hours for 1 week; Diclofenac sodium injection (75 mg, amp) as needed	Alfuzosin 10 mg Tamsulosin 0.4 mg Control	4	3
Sameer[17]	India	2014	35 35	6.26 6.37	LU	Diclofenac sodium (50 mg, tablet) every 12 hours for 1 week; Diclofenac sodium injection (75 mg, amp) as needed	Alfuzosin 10 mg Control	4	5
Morua[19]	Mexico	2009	15 15	5.80 6.43	LU	Buscopan 10 mg/8h plus ketorolac 10 mg/8h	Alfuzosin 10 mg Control	4	2

NR = not record; UU = upper ureter; LU = lower ureter; F = follow-up

^# Control group receiving placebo or dologesic

* Using Jadad scale (score from 0 to 5)